<DOC>
	<DOCNO>NCT01204528</DOCNO>
	<brief_summary>To investigate whether treatment vitamin-D receptor activator able improve important marker cardiovascular risk .</brief_summary>
	<brief_title>Vitamin-D Receptor Activation ( VDRA ) Chronic Kidney Disease</brief_title>
	<detailed_description>Main question : May 12 week VDRA treatment reduce pathological sympathetic overactivation associate moderate kidney disease ? Secondary question aim thrown light VDRAs reduce albuminuria CRP , i.e . VDRA treatment improve ( prespecified statistical analysis ) : A ) diastolic dysfunction ? B ) capillary microcirculation , whether ameliorated disturbance relate improve diastolic dysfunction ? C ) endothelial dysfunction arterial stiffness ? D ) inflammatory activation ? E ) platelet function haemostasis ? F ) level antibacterial peptide ? G ) level IGFBP-1 adiponectin ? Overall design The study design double-blind , randomise , placebo-controlled trial involve two group ( n=72 ) patient : 1 ) chronic kidney failure ( CKD , eGFR 15-59 mL/m2 ) 2 ) chronic kidney failure concomitant diabetes mellitus ( CKD+DM ) . It start two-week placebo run-in , follow randomisation : 1 . Zemplar 1 μg ( take 1 x 1 μg capsule one placebo capsule ) , 2 . Zemplar 2 μg ( take 2 x 1 μg capsule ) 3. placebo ( take two placebo capsule ) .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>eGFR 1559 ml/m2 Current vitamin D treatment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Dysfunction CKD</keyword>
</DOC>